MEDBOT-B (02252) saw its shares rise more than 4%. At the time of writing, the stock was up 3.44% to HK$28.28, with a turnover of HK$42.44 million. The positive movement follows a research report highlighting the company's 2026 fiscal year guidance, which signals a clear shift from "commercial validation" to "profit realization." Management has set definitive targets for revenue, profitability, and cash flow. The company anticipates revenue this year to reach approximately RMB 1.1 billion, nearly doubling year-on-year, while also achieving a transition from break-even to net profit and generating positive free cash flow, indicating it is entering an operational leverage phase. As of early April, the company had installed 23 Toumai surgical robots and held a backlog of 86 units. Management guides for installations of approximately 103 to 113 units in the first half of the year, with a full-year target of at least 200 units, confirming that delivery bottlenecks experienced in the second half of last year have been resolved. The overseas market is expected to remain the core growth engine, with demand spanning Europe, Asia (excluding China), and Latin America.